Dr. Alexander Pushka, MD
Child & Adolescent Psychiatry (Child & Adolescent Psychiatry Physician)
- Medicare participating
At a glance
- Years since graduation
- 46
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 283
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Child & Adolescent Psychiatry Physician primary
FL license ME88666 · NC license 2023-02477 -
Psychiatry Physician
FL license ME88666 · NC license 2023-02477
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Regional Hospital Hollywood, FL
Medical groups
- Advanced Psychiatric Services Professional Association (7 clinicians)
- Alexander Pushka MD PA (6 clinicians)
- Advanced Psychiatric Services PLLC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 283
- Services billed
- 2,272
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 946 | 93 |
| Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | 367 | 101 |
| Psychotherapy with evaluation and management visit, 30 minutes | 286 | 49 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 222 | 53 |
| Established patient office or other outpatient visit, 30-39 minutes | 203 | 36 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 130 | 111 |
| Residence visit for established patient with low level of medical decision making, per day, if using time, at least 30 minutes | 115 | 17 |
| Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | 109 | 108 |
| Hospital discharge day management, more than 30 minutes | 68 | 56 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 31 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Quetiapine Fumarate Other prescribers in Hollywood, FL | 235 |
| Clonazepam Other prescribers in Hollywood, FL | 194 |
| Alprazolam Other prescribers in Hollywood, FL | 162 |
| Lorazepam Other prescribers in Hollywood, FL | 145 |
| Olanzapine Other prescribers in Hollywood, FL | 138 |
| Duloxetine Hcl Other prescribers in Hollywood, FL | 130 |
| Sertraline Hcl Other prescribers in Hollywood, FL | 128 |
| Bupropion Xl (bupropion hcl) Other prescribers in Hollywood, FL | 122 |
| Invega Sustenna (paliperidone palmitate) Other prescribers in Hollywood, FL | 120 |
| Escitalopram Oxalate Other prescribers in Hollywood, FL | 117 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 91 payments worth $2,059 in total to this clinician.
| Alkermes, Inc. | $419 |
|---|---|
| Neurocrine Biosciences, Inc. | $351 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) | $349 |
| Teva Pharmaceuticals USA, Inc. | $251 |
| Almatica Pharma LLC | $205 |
| Janssen Pharmaceuticals, Inc | $183 |
| Axsome Therapeutics, Inc. | $156 |
| Collegium Pharmaceutical, Inc. | $40.95 |
| Food and Beverage | $2,059 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $205,091 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD)…
Janssen Research & Development, LLC - Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
Acadia Pharmaceuticals Inc · Recruiting · NCT07029581 - ACP-204-013
Acadia Pharmaceuticals Inc - A phase 3, multicenter, long-term, extension study of the safety and efficacy of AVP-786 (deuterated [D6] dextromethorphan hydrobromide [D6-dm]/quinidine sulfate [q]) for the treatment of agitation in patients with de…
Otsuka Pharmaceutical Development & Commercialization, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.